| |
 | |
 |
|
 |
|
 |
|
 |
|
| |
 |
|
 |
|
 |
|
 |
|
 | |
 |
|
 |
 |
 |
 |
 |
 |
 |
|
 |
Erik Anderson 12790 El Camino Real |
|
Legal Areas of Emphasis Patents Intellectual Property Litigation Right-to-Practice Opinions Intellectual Property Due Diligence Technical Areas of Emphasis Pharmaceuticals Biotechnology Chemical Medical Devices Professional Profile Erik T. Anderson is partner in our San Diego office. He specializes in patents and other forms of intellectual property protection, primarily for biotech and chemistry-related technologies.
Mr. Anderson’s practice includes patent procurement, freedom-to-operate opinions, intellectual property litigation, and general counseling on infringement and licensing issues. He represents a number of clients in biotechnology and the chemical arts, with particular emphasis on pharmaceuticals, molecular biology, and electrochemistry.
Prior to joining the firm, from 1996 to 1998, Mr. Anderson was a research chemist for the National Cancer Institute. Working in the Chemical Synthesis and Analysis Laboratory, he isolated experimental anti-tumor agents and performed analytical techniques including HPLC, TLC, NMR, FT-IR, UV, and mass spectra analysis.
Mr. Anderson joined the firm in 2001 and became a partner in 2008. Education Arizona State University College of Law (J.D. 2001) cum laude Order of the Coif Legal Honor Society Senior Editor of Jurimetrics Law Journal Co-founder of the Intellectual Property Student Association University of Maryland (B.S. Chemistry 1996)
Representative Matters Pfizer Inc., et al. v. Ranbaxy Pharms., et al., (D.N.J. 2003-2007). Pharmaceuticals. Represented defendants in multi-district patent litigation relating to gabapentin (active ingredient in Pfizer’s Neurontin® anti-seizure product). Achieved favorable, case-dispositive settlement in which client remained on the market.
Aventis Pharms., et al. v. Ranbaxy Labs. Ltd., (D.N.J./Fed. Cir. 2003-2009). Pharmaceuticals. Represented defendants in coordinated patent litigation regarding fexofenadine (active ingredient in Aventis’ Allegra® antihistimine product). Obtained, and successfully sustained on appeal, denial of preliminary injunction.
Roche Palo Alto LLC v. Ranbaxy Labs. Ltd., (D.N.J. 2006- ). Pharmaceuticals. Representing defendant in patent litigation regarding valganciclovir (active ingredient in Roche’s Valcyte® anti-viral product). Admissions/Qualifications State Bar of California All U.S. District Courts in California District of Columbia Bar U.S. District Court for the District of Columbia U.S. Court of Appeals for the Federal Circuit Registered to practice before the U.S. Patent and Trademark Office Professional Memberships & Affiliations American Bar Association San Diego County Bar Association Teaching/Adjunct Professor University of California, San Diego Principles of Copyrights Principles of Patents Thomas Jefferson School of Law Patent Law Articles, Speeches & Seminars Author of "Protection of Trademarks from Use in Internet Advertising Banner Triggers: Playboy v. Netscape" published in Jurimetrics 40:469 (2000).
Awards & Honors Mr. Anderson was selected as a San Diego Top Attorney Semi-Finalist for Intellectual Property Litigation in a survey of his peers in 2009. |
© 2010 Knobbe Martens Olson & Bear LLP a Limited Liability Partnership including Professional Corporations.